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Core Medicines for Quality Care of the Dying
Paul A. Tait, BPharm, MClin Pharm, MSHP and Timothy H. M. To, BSc, BMBS, FRACP
Dear Editor:
The proposal by Lindqvist and colleagues1 of four essential
medicines for the control of terminal symptoms is com-
mendable. Having a finite essential medication list facilitates
prescribers to prescribe and pharmacies to stock and supply
medications to support end-of-life care in the community.2
With this issue in mind, a recent collaboration of South
Australian palliative care clinicians developed a core medi-
cines list for the treatment of symptoms commonly seen at the
end of life. As for Lindqvist’s model, we also involved
widespread consultation with key palliative care stakehold-
ers. We employed a number of criteria, partly informed by
Rowett3 in the development of our list, including
 Evaluation of the medical literature
 Cost (including the availability of government sub-
sidies)
 Medicines that are able to address more than one
symptom
 Route(s) of administration
Our core medicines include
 Clonazepam
 Haloperidol
 Hyoscine butylbromide
 Metoclopramide
 Morphine
The differences between the two lists are the choices of ben-
zodiazepine and anticholinergic, and the inclusion of meto-
clopramide.
Both midazolam and clonazepam are used for symptom
control at the end of life. However midazolam’s short dura-
tion of action means a syringe driver is required for lasting
effect, which may be unavailable at short notice. Therefore,
with community patients in mind, we proposed clonazepam
as our benzodiazepine of choice. In Australia, clonazepam
is also eligible for government subsidy, thus cheaper than
injectable midazolam for patients. We selected hyoscine
butylbromide because of its inability to cross the blood brain
barrier tominimize central anticholinergic effects, particularly
sedation and delirium, for patients who are still conscious.
Each list was developed to facilitate high-quality symptom
control at the end of life for community patients. Regional
licensing and subsidy will influence the exact medications on
such lists. However with essential medication lists, the im-
perative is to educate both prescriber and pharmacist to en-
sure the medications prescribed at the end of life will be
available for the patient in his or her time of great need.
Without education, the risk is the prescriber, through personal
preference, will prescribe medications outside the list and
compromise the symptom control of the patient at the end of
life simply because the pharmacist is unable to anticipate
which medicines to stock.
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